IRIS
MUTTI, LUCIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.254
AS - Asia 2.263
EU - Europa 1.929
SA - Sud America 355
Continente sconosciuto - Info sul continente non disponibili 154
AF - Africa 45
AN - Antartide 1
Totale 10.001
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.100
SG - Singapore 1.075
RU - Federazione Russa 620
IT - Italia 617
CN - Cina 432
HK - Hong Kong 378
IE - Irlanda 333
BR - Brasile 291
VN - Vietnam 199
FR - Francia 121
CA - Canada 93
GB - Regno Unito 76
DE - Germania 45
IN - India 32
FI - Finlandia 28
BD - Bangladesh 23
MX - Messico 22
JP - Giappone 19
AR - Argentina 18
TR - Turchia 17
CO - Colombia 14
ES - Italia 14
SE - Svezia 14
ZA - Sudafrica 14
IQ - Iraq 13
NL - Olanda 11
PL - Polonia 10
ID - Indonesia 9
MY - Malesia 9
PK - Pakistan 8
SA - Arabia Saudita 8
UA - Ucraina 8
UZ - Uzbekistan 8
BE - Belgio 7
VE - Venezuela 7
EC - Ecuador 6
HN - Honduras 6
MA - Marocco 6
PY - Paraguay 6
AE - Emirati Arabi Uniti 5
EE - Estonia 5
KE - Kenya 5
LT - Lituania 5
PR - Porto Rico 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
BB - Barbados 4
CL - Cile 4
JM - Giamaica 4
CR - Costa Rica 3
EG - Egitto 3
GP - Guadalupe 3
JO - Giordania 3
KR - Corea 3
NP - Nepal 3
OM - Oman 3
PE - Perù 3
RO - Romania 3
SN - Senegal 3
TN - Tunisia 3
CW - ???statistics.table.value.countryCode.CW??? 2
CZ - Repubblica Ceca 2
GR - Grecia 2
GT - Guatemala 2
KG - Kirghizistan 2
NG - Nigeria 2
NI - Nicaragua 2
PH - Filippine 2
SC - Seychelles 2
SR - Suriname 2
TH - Thailandia 2
UY - Uruguay 2
ZW - Zimbabwe 2
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
AT - Austria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CD - Congo 1
CH - Svizzera 1
CU - Cuba 1
DZ - Algeria 1
GD - Grenada 1
GY - Guiana 1
IL - Israele 1
KH - Cambogia 1
KY - Cayman, isole 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
ME - Montenegro 1
MF - Saint Martin 1
PS - Palestinian Territory 1
RS - Serbia 1
RW - Ruanda 1
SI - Slovenia 1
SV - El Salvador 1
Totale 9.849
Salva come PNG Salva come JPEG
Città #
San Jose 927
Singapore 585
Ashburn 555
Council Bluffs 519
Dallas 398
Hong Kong 367
Santa Clara 356
Dublin 332
Boardman 192
The Dalles 175
Moscow 140
Milan 126
Lauterbourg 110
Los Angeles 87
Beijing 84
Hefei 83
New York 78
Assago 76
Ho Chi Minh City 56
Hanoi 52
Phoenix 51
Rome 49
Chicago 39
Atlanta 34
São Paulo 31
Brooklyn 29
Miano 22
Naples 22
Montreal 20
Tokyo 19
Da Nang 17
Falkenstein 16
Orem 16
Toronto 16
Columbus 14
Munich 14
Stockholm 14
Helsinki 13
San Francisco 13
Chennai 12
Florence 12
Bari 11
Boston 11
Charlotte 11
Denver 11
Lappeenranta 11
L’Aquila 11
Mexico City 11
North Bergen 11
Catania 10
Manchester 10
Seattle 10
Warsaw 10
Buffalo 9
London 9
Palermo 9
Turin 9
Johannesburg 8
Ninh Bình 8
Rio de Janeiro 8
Amsterdam 7
Genoa 7
Philadelphia 7
Tashkent 7
Brasília 6
Erbil 6
Frankfurt am Main 6
Houston 6
Piscataway 6
Secaucus 6
Shanghai 6
Washington 6
Ankara 5
Brussels 5
Cagliari 5
Calgary 5
Dhaka 5
Guangzhou 5
Kansas City 5
Milwaukee 5
Nairobi 5
Ottawa 5
Pittsburgh 5
Poplar 5
Baku 4
Birmingham 4
Bologna 4
Bridgetown 4
Bắc Ninh 4
Curitiba 4
Haiphong 4
Hangzhou 4
Jackson 4
Karachi 4
Las Vegas 4
Manhuaçu 4
Mumbai 4
Oklahoma City 4
Paris 4
Querétaro 4
Totale 6.159
Salva come PNG Salva come JPEG
Nome #
Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells 979
Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations 110
Intratumor microbiota as a novel potential prognostic indicator in mesothelioma 109
PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach 109
{CONFIRM} trial: what is the real efficacy of second-line immunotherapy in mesothelioma? 107
Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma 106
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology 105
The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review 99
The function and clinical implication of YTHDF1 in the human system development and cancer 94
European Respiratory Society Guideline on various aspects of quality in lung cancer care 94
TNF-α determination in serum and pleural effusion in patients with lung cancer 92
A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma 90
Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal End Point? 90
P53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification 89
Neuro–Immune Interactions in Severe COVID-19 Infection 86
HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy 85
Identification and Validation of Long Non-Coding RNA LCIIAR as a Biomarker in LUAD 84
Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo 82
The function and clinical implication of circular RNAs in lung cancer 82
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial 81
Abemaciclib for malignant pleural mesothelioma 81
Association of SV40 with human tumours 79
Chemoprevention of asbestos-linked cancers: A systematic review 79
Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia 77
Genetic susceptibility to malignant mesothelioma and exposure to asbestos: The influence of the familial factor 77
Over-Expression of Long Non-Coding RNA-AC099850.3 Correlates With Tumor Progression and Poor Prognosis in Lung Adenocarcinoma 77
Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation 76
Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma 74
When Ron met Tam in mesothelioma: All druggable for one, and one drug for all? 74
CDK4, CDK6/cyclin‐d1 complex inhibition and radiotherapy for cancer control: A role for autophagy 73
Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro 73
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy 72
Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VII th Meeting of the International Mesothelioma Interest Group 71
Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines 71
Targeting hypoxic response for cancer therapy 70
Simian virus 40 and malignant mesothelioma (Review) 70
Preclinical Demonstrations of Synergistic Active Nutrient/Drug (and) Combination as a Potential Treatment for Malignant Pleural Mesothelioma 70
In vivo effect of human granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil GM-CSF receptors 70
Erionite and asbestos differently cause transformation of human mesothelial cells 69
A molecular epidemiology case control study on pleural malignant mesothelioma 68
Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution 68
Editorial: Prognostic factors in non-small cell lung cancer 68
Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma 68
Blood cell redistribution in the lung after administration of recombinant human granulocyte-macrophage colony-stimulating factor 68
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma 68
Recurrent chromosome 6 abnormalities in malignant mesothelioma 67
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma 67
What can independent research for mesothelioma achieve to treat this orphan disease? 67
Epigallocatechin-3-gallate induces mesothelioma cell death via H2O2-dependent T-type Ca2+ channel opening 66
Comparison between plasma and serum osteopontin levels: Usefulness in diagnosis of epithelial malignant pleural mesothelioma 66
Sirtuin Family Members Selectively Regulate Autophagy in Osteosarcoma and Mesothelioma Cells in Response to Cellular Stress 65
Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer 65
Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis 65
Editorial: Editor's challenge: Dr. Luciano Mutti - what is the true impact of ICIs on survival in the treatment of thoracic malignancies? 65
Cancer testis antigens expression in mesothelioma: Role of DNA methylation and bioimmunotherapeutic implications 65
Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma 64
SV40 and human brain tumors [2] 64
Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts 64
Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma 64
Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer 64
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients 64
Will antiangiogenic agents be a future for mesothelioma therapy? 63
SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure 63
A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people 63
Erratum: Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma (Genes, Chromosomes and Cancer (2000) 29 (173-179)) 63
Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo 62
Variations in aspecific bronchial reactivity elicited by methacholine in chronic bronchitis patients treated with doxofylline. Double blind cross-over study versus theophylline slow-release 61
Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase 61
Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma 61
Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to Gefitinib 61
New standard for assessing asbestos exposure and its consequences? 61
Bortezomib inhibits nuclear factor-κB-dependent survival and has potent in vivo activity in mesothelioma 60
Study of the combined role of asbestos and SV40 in the pathogenesis of malignant mesothelioma 60
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma 60
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 59
Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism 59
Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma 59
Evaluation of a series of serum mesothelin in patients with pleural Malignant Mesothelioma 58
Establishment of four new mesothelioma cell lines: Characterization by ultrastructural and immunophenotypic analysis 58
Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas 58
BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment 57
SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: A molecular epidemiologic case-control study 57
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 57
Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients 57
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 56
New agents in the management of advanced mesothelioma 56
Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma 56
Simian Virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey 55
Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone 55
Expression of glycoprotein 90K in human malignant pleural mesothelioma: Correlation with patient survival 55
Current and prospective pharmacotherapies for the treatment of pleural mesothelioma 54
In arrayed ranks array technology in the study of mesothelioma steven 54
Anti-CTLA-4 therapy for malignant mesothelioma 54
Translational therapies for malignant pleural mesothelioma 54
The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor 54
Taurolidine and oxidative stress: A rationale for local treatment of mesothelioma 54
Scientific Advances and New Frontiers in Mesothelioma Therapeutics 54
Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: A feasibility study 53
Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma 52
MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma 52
Totale 7.872
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.151
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.151
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023395 0 0 0 0 0 0 0 53 327 0 4 11
2023/2024354 7 13 18 55 19 141 0 7 3 26 24 41
2024/20252.387 176 28 153 30 215 266 240 109 658 119 235 158
2025/20264.101 172 455 333 396 317 237 933 154 368 360 351 25
2026/20272.764 1.039 235 484 1.006 0 0 0 0 0 0 0 0
Totale 10.001